Invex Therapeutics (ASX: IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute strok...See more
Headquarters:
Australia
Company Type:
MNC / Large Enterprise
Company size:
1-10 Employees
Year Founded:
2019 (7 years)
Address:
38 ROWLAND STREET; LEVEL 1; SUBIACO, WA 6008, AU
LOW
spending power
